0000899243-18-016532.txt : 20180614
0000899243-18-016532.hdr.sgml : 20180614
20180614083448
ACCESSION NUMBER: 0000899243-18-016532
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180612
FILED AS OF DATE: 20180614
DATE AS OF CHANGE: 20180614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SMITH IAN F
CENTRAL INDEX KEY: 0001197032
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31141
FILM NUMBER: 18898205
MAIL ADDRESS:
STREET 1: C/O ACORDA THERAPEUTICS, INC.
STREET 2: 420 SAW MILL RIVER ROAD
CITY: ARDSLEY
STATE: NY
ZIP: 10502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001113148
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330655706
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 784 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6174531000
MAIL ADDRESS:
STREET 1: 784 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/
DATE OF NAME CHANGE: 20060913
FORMER COMPANY:
FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC
DATE OF NAME CHANGE: 20000428
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-12
0
0001113148
INFINITY PHARMACEUTICALS, INC.
INFI
0001197032
SMITH IAN F
C/O INFINITY PHARMACEUTICALS, INC.
784 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2018-06-12
4
A
0
22857
1.75
A
45845
D
Stock Option (right to buy)
1.75
2018-06-12
4
A
0
20000
0.00
A
2028-06-12
Common Stock
20000
20000
D
Stock Option (right to buy)
1.75
2018-06-12
4
A
0
4000
0.00
A
2028-06-12
Common Stock
4000
4000
D
Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.
The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.
/s/ Ian F. Smith
2018-06-12